Login to Your Account


LONDON – Psioxus Therapeutics Ltd. has received approval for a phase I trial of NG-348, the first of its gene therapy for tumor products, triggering a $15 million milestone from partner Bristol-Myers Squibb Co. (BMS).

LONDON – The European pharma industry has united with patients groups as well as health care professionals in calling for a deal for the sector to be given priority now that the U.K. has cleared the barriers to enter phase two of the Brexit negotiations.

LONDON – The government has unveiled a package of investments by 25 life science companies, which it says demonstrates the U.K. remains an attractive place to invest despite Brexit.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: